Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15149262 | 0.72 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL708733 | 0.71 | CHRM2 (0.46) | HSD11B1 | |
| SCHEMBL699340 | 0.70 | CHRM2 (0.38) | HSD11B1 | |
| SCHEMBL699442 | 0.70 | SMN1; SMN2 (0.46) | HSD11B1 | |
| SCHEMBL1237992 | 0.70 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL699339 | 0.69 | CHRM2 (0.37) | HSD11B1 | |
| Adamantane SCHEMBL851674 | 0.66 | CYP2C9 (0.41) | HSD11B1 | |
| SCHEMBL19798467 | 0.66 | CHRM2 (0.62) | HSD11B1 | |
| SCHEMBL3424501 | 0.65 | CHRNB2 (0.50) | HSD11B1 | |
| SCHEMBL17331177 | 0.65 | HSD11B1 (0.40) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8669367-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | HSD11B1 21/4885 |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | HSD11B1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.